期刊文献+
共找到502篇文章
< 1 2 26 >
每页显示 20 50 100
Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy—Are We There Yet?
1
作者 Kevin Yap Cassandra Leong Alexandre Chan 《Journal of Cancer Therapy》 2012年第1期90-102,共13页
Chemotherapy-induced nausea and vomiting (CINV) are distressing side effects of chemotherapy. Neurokinin-1 receptor antagonists (NK1-RAs) have been incorporated in the contemporary management of CINV. However, clinica... Chemotherapy-induced nausea and vomiting (CINV) are distressing side effects of chemotherapy. Neurokinin-1 receptor antagonists (NK1-RAs) have been incorporated in the contemporary management of CINV. However, clinical studies on NK1-RAs have shown mixed results in reducing CINV risk. Most studies focused on the use of aprepitant (APR) and casopitant (CAS) in breast cancer patients receiving AC-type (doxorubicin and cyclophosphamide) chemotherapy. In this study, we compared the study design and clinical efficacies of these NK1-RAs in reducing CINV risk. Among the selected eight studies, 4 APR Randomized Controlled Trials (RCTs), 2 APR Observational Studies (OSs) and 2 CAS RCTs were identified. Patient-related characteristics such as the proportion of females (60.0% - 100.0%), age (46.5 - 59.5 years), histories of motion (5.6% - 47.0% in NK1-RA arms) and morning sicknesses (14.2% - 45.0% in NK1-RA arms) and types of antiemetic regimens;as well as chemotherapy-related characteristics such as the proportion of patients on AC chemotherapy (15.0% - 100.0%) varied greatly. In terms of efficacies, both APR and CAS improved overall CR and vomiting in majority of the studies. None of the studies, however, demonstrated that NK1-RA could provide adequate nausea control. To conclude, NK1-RAs are effective in improving vomiting and overall CR, but not useful in controlling nausea or attaining CC, the ideal CINV endpoint. A shift in paradigm is needed for future CINV research. As healthcare providers continue to strive for optimum CINV control in their patients, we hope this review can help them make better informed clinical decisions. 展开更多
关键词 AC Anthracycline-Based CHEMOTHERAPY APREPITANT Breast Cancer CASOPITANT Chemotherapy-Induced Nausea Vomiting neurokinin-1 receptor antagonistS (NK1-RAs)
下载PDF
Advances in the research and application of neurokinin-1 receptor antagonists
2
作者 Xiangyu HONG Junjie MA +2 位作者 Shanshan ZHENG Guangyu ZHAO Caiyun FU 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 SCIE CAS CSCD 2024年第2期91-105,共15页
Recently,the substance P(SP)/neurokinin-1 receptor(NK-1R)system has been found to be involved in various human pathophysiological disorders including the symptoms of coronavirus disease 2019(COVID-19).Besides,studies ... Recently,the substance P(SP)/neurokinin-1 receptor(NK-1R)system has been found to be involved in various human pathophysiological disorders including the symptoms of coronavirus disease 2019(COVID-19).Besides,studies in the oncological field have demonstrated an intricate correlation between the upregulation of NK-1R and the activation of SP/NK-1R system with the progression of multiple carcinoma types and poor clinical prognosis.These findings indicate that the modulation of SP/NK-1R system with NK-1R antagonists can be a potential broad-spectrum antitumor strategy.This review updates the latest potential and applications of NK-1R antagonists in the treatment of human diseases and cancers,as well as the underlying mechanisms.Furthermore,the strategies to improve the bioavailability and efficacy of NK-1R antagonist drugs are summarized,such as solid dispersion systems,nanonization,and nanoencapsulation.As a radiopharmaceutical therapeutic,the NK-1R antagonist aprepitant was originally developed as radioligand receptor to target NK-1R-overexpressing tumors.However,combining NK-1R antagonists with other drugs can produce a synergistic effect,thereby enhancing the therapeutic effect,alleviating the symptoms,and improving patients’quality of life in several diseases and cancers. 展开更多
关键词 neurokinin-1 receptor(NK-1R)antagonist Pathophysiological disorder Tumor target BIOAVAILABILITY NANOENCAPSULATION Synergistic therapy
原文传递
白细胞介素1受体颉颃剂抑制脂多糖促奶牛外周血单个核细胞氧化应激损伤作用的研究
3
作者 郭咏梅 齐敬宇 +2 位作者 闫素梅 赵艳丽 郭晓宇 《饲料工业》 CAS 北大核心 2024年第4期100-105,共6页
试验以脂多糖(LPS)为刺激源,以细胞活力、抗氧化指标和炎症因子为判断指标,探讨白细胞介素1受体颉颃剂(IL-1Ra)通过抑制白细胞介素1β(IL-1β)的活性,对LPS诱导外周血单个核细胞(Peripheral blood mononuclear cells,PBMCs)氧化损伤的... 试验以脂多糖(LPS)为刺激源,以细胞活力、抗氧化指标和炎症因子为判断指标,探讨白细胞介素1受体颉颃剂(IL-1Ra)通过抑制白细胞介素1β(IL-1β)的活性,对LPS诱导外周血单个核细胞(Peripheral blood mononuclear cells,PBMCs)氧化损伤的缓解作用。试验采用单因子完全随机设计,PBMCs被随机分为7个组(每组6个重复),分别给予不同的处理:第1组是阴性对照组(Neg组),完全培养基培养30 h;第2组损伤组(Dam组),是在完全培养基中培养6 h后,再经10μg/mL的LPS工作液培养24 h;第3至7组(R0.25、R0.5、R1、R5组和R10组)细胞分别经浓度为0.25、0.5、1、5、10 ng/mL的IL-1Ra培养6 h,接着经10μg/mL的LPS工作液培养24 h。结果表明:与Neg组相比,Dam组的细胞活力、抗氧化相关酶[包括总抗氧化能力(T-AOC)以及总超氧化物歧化酶(T-SOD)、过氧化氢酶(CAT)、谷胱甘肽过氧化物酶(GPx)和硫氧还蛋白还原酶(TrxR)]的活性显著降低,丙二醛(MDA)浓度、炎症因子白细胞介素-6(IL-6)和IL-1β含量以及诱导型一氧化氮合酶(iNOS)活性、一氧化氮(NO)含量均显著升高(P≤0.05)。与Dam组相比,R1组显著逆转了氧化损伤引起的上述抗氧化活性的降低和炎症因子浓度的升高,其他IL-1Ra处理组对上述指标的逆转效果不同程度地低于R1组(P≤0.05)。上述结果说明,LPS通过诱发PBMCs产生大量IL-1β进而导致细胞氧化损伤,IL-1Ra剂量依赖性地缓解了LPS引起的氧化损伤,添加剂量以1 ng/mL为宜。 展开更多
关键词 奶牛外周血单个核细胞 氧化应激 剂量依赖性 白细胞介素1受体颉颃剂 预保护作用
下载PDF
Effects of AT1 receptor antagonist,Iosartan,on rat hepatic fibrosis induced by CCl_4 被引量:42
4
作者 Hong Shan Wei Ding Guo Li Han Ming Lu Yu Tao Zhan Zhi Rong Wang Xin Huang Jing Zhang Ji Lin Cheng Qin Fang Xu Department of Gastroenterology,Xinhua Hospital,Shanghai Second Medical University,Shanghai 200092,China 《World Journal of Gastroenterology》 SCIE CAS CSCD 2000年第4期540-545,共6页
AIM To investigate effect of losartan,an AT1receptor antagonist,on hepatic fibrosis induced byCCl<sub>;</sub>and to determine whether or not AT1receptors are expressed on hepatic stellate cells,METHODS AND... AIM To investigate effect of losartan,an AT1receptor antagonist,on hepatic fibrosis induced byCCl<sub>;</sub>and to determine whether or not AT1receptors are expressed on hepatic stellate cells,METHODS AND RESULTS Fifty male Sprague-Dawley rats,weighing(180±20)g,wererandomized into five groups(control group,modelgroup,and three losartan treated groups),inwhich all rats were given the subcutaneousinjection of 40% CCl<sub>4</sub>(every 3 days for 6 weeks)except for rats of control group.Rats of losartan-treated groups were treated with losartan(20 mg/kg,10 mg/kg,5 mg/kg,daily gavage),After 6weeks liver tissue and serum samples of all ratswere examined.Serum hyaluronic acid(HA),procollagen typeⅢ(PCⅢ)were detected byradioimmunoassays,van Giesion collagen stainingwas used to evaluate the extracellular matrix of ratswith liver fibrosis.The expression of AT1receptors,transforming growth factor-beta(TGF-β),and alpha-smooth muscle actin(a-SMA)inliver tissue were determined byimmunohistochemical techniques.Compared withmodel group,serum ALT and AST of losartan-treated groups were significantly reduced(t=4.20,P【0.01 and t=4.57,P【0.01).Serum HAand PCⅢalso had significant differences(t=3.53,P【0.01 and t=2.20,P【0.05).Thedegree of fibrosis was improved by losartan and correlated with the expressions of AT1 receptors,TGF-β,and α-SMA in liver tissue.CONCLUSION AT1 receptor antagonist,losartan,could limit the progression of the hepatic fibrosisinduced by CCl<sub>4</sub>.The mechanism may be related tothe decrease in the expression of AT1 receptorsand TGF-β,ameliorating the injury of hepatocytes;activation of local renin-angiotensin system mightrelate to hepatic fibrosis;and during progressionof fibrosis,activated hepatic stellate cells mightexpress AT1 receptors. 展开更多
关键词 liver cirrhosis/drug therapy RENIN-ANGIOTENSIN system ANGIOTENSIN type 1 receptor antagonist LOSARTAN
下载PDF
Effect evaluation of interleukin-1 receptor antagonist nanoparticles for mesenchymal stem cell transplantation 被引量:3
5
作者 Xiao-Lei Shi Wei Zhu +5 位作者 Jia-Jun Tan Jiang-Qiang Xiao Lin Zhang Qian Xu Zheng-Liang Ma Yi-Tao Ding 《World Journal of Gastroenterology》 SCIE CAS 2013年第12期1984-1991,共8页
AIM: To study the efficacy of marrow mesenchymal stem cells (MSCs) transplantation combined with interleukin-1 receptor antagonist (IL-1Ra) for acute liver failure (ALF). METHODS: Chinese experimental miniature swine ... AIM: To study the efficacy of marrow mesenchymal stem cells (MSCs) transplantation combined with interleukin-1 receptor antagonist (IL-1Ra) for acute liver failure (ALF). METHODS: Chinese experimental miniature swine were randomly divided into four groups (n = 7), and all animals were given D-galactosamine (D-gal) to induce ALF. Group A animals were then injected with 40 mL saline via the portal vein 24 h after D-gal induction;Group B animals were injected with 2 mg/kg IL-1Ra via the ear vein 18 h, 2 d and 4 d after D-gal induction; Group C received approximately 1 × 108 green fluorescence protein (GFP)-labeled MSCs (GFP-MSCs) suspended in 40 mL normal saline via the portal vein 24 h after D-gal induction; Group D animals were injected with 2 mg/kg IL-1Ra via the ear vein 18 h after D-gal induction, MSCs transplantation was then carried out at 24 h after D-gal induction, and finally 2 mg/kg IL-1Ra was injected via the ear vein 1 d and 3 d after surgery as before. Liver function, serum inflammatory parameters and pathological changes were measured and the fate of MSCs was determined.RESULTS: The optimal efficiency of transfection (97%) was achieved at an multiplicity of infection of 80, as observed by fluorescence microscopy and flow cytometry (FCM). Over 90% of GFP-MSCs were identified as CD44+ CD90+ CD45-MSCs by FCM, which indicated that most GFP-MSCs retained MSCs characteristics. Biochemical assays, the levels of serum inflammatory parameters and histological results in Group D all showed a significant improvement in liver injury compared with the other groups (P < 0.05). The number of GFP-MSCs in Group D was also greater than that in Group B, and the long-term cell proliferation rate was also better in Group D than in the other groups.CONCLUSION: MSCs transplantation is useful in ALF, IL-1Ra plays an important role in alleviating the inflammatory condition, and combination therapy with MSCs transplantation and IL-1Ra is a promising treatment for ALF. 展开更多
关键词 INTERLEUKIN-1 receptor antagonist MESENCHYMAL stem cells Cell TRANSPLANTATION Acute liver failure INFLAMMATORY environment
下载PDF
Study on Immunoregulation by Interleukin-1 ReceptorAntagonist in NZB/W F_1 Mice 被引量:1
6
作者 孙汉英 刘文励 +3 位作者 邵静芳 徐慧珍 肖侃艳 沈关心 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 1997年第1期18-20,24,共4页
The immunoregulating effect of Interleukin-1-receptor antagonist (ILlra ) in lupus-like NZB/W F, mice was investigated to find possible approach to prevent lupus nephritis. 12 female NZB/W F1 mice of 13 weeks were ran... The immunoregulating effect of Interleukin-1-receptor antagonist (ILlra ) in lupus-like NZB/W F, mice was investigated to find possible approach to prevent lupus nephritis. 12 female NZB/W F1 mice of 13 weeks were randomly divlded into 2 groups. Each mouse in the treated group was intraperitoneally injected wlth IL-lra once every 2 weeks for 3 times at the dosage of 100μg each time,while the control group was given injection of 0.1 ml normal saline. All the mice were killed at the age of 9 months and the irnmunologic function was examined.Results showed that this dosage could not completely prevent the development of lupus nephritis, but the renal damage was alleviated and the urine protein was decreased. Moreover, it could improve the immunofunction by significantly reducing the levels of serum IL-1 and obviously increase the activities of NK celIs and IL-2 induced by ConA in mononuclear cells of spleen. There was no significant difference in the levels of serum IL-6 and TNF-α between the treated group and control group. It is concluded that IL-lra has certain regulatory effect on the immunologic function of lupus-like NZB/W F, mice. 展开更多
关键词 interleukin-1 receptor antagonist systemic lupus erythematosis immune system
下载PDF
Correlation of polymorphism in the interleukin-1 receptor antagonist gene intron 2 with alcoholic liver disease 被引量:1
7
《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2005年第1期41-45,共5页
关键词 INTERLEUKIN-1 receptor antagonist GENE POLYMORPHISM ALCOHOLIC liver disease
下载PDF
Effect of endothelin-1 receptor antagonists on histological and ultrastructural changes in the pancreas and trypsinogen activation in the early course of caerulein-induced acute pancreatitis in rats 被引量:3
8
作者 Anna Andrzejewska Jan W.Dlugosz Albert Augustynowicz 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第8期1115-1121,共7页
AIM: To assess the effect of non-selective ETA/B (LU 302872)and selective ETA (LU 302146) antagonist on pancreatic histology and ultrastructure of acinar cells in connection with trypsinogen activation in early caerul... AIM: To assess the effect of non-selective ETA/B (LU 302872)and selective ETA (LU 302146) antagonist on pancreatic histology and ultrastructure of acinar cells in connection with trypsinogen activation in early caerulein-induced AP.METHODS: Male Wistar rats with caerulein-induced AP,lasting 4 h, were treated i.p. with 10 and 20 mg/kg b.w.of each antagonist. Edema, inflammatory infiltration,necrosis and vacuolization of acinar cells in the pancreas were scored at 0-3 scale. Free active trypsin (FAT), total potential trypsin (TPT) after activation with enterokinase,and index of trypsinogen activation (%FAT/TPT) were assayed in pancreatic homogenates.RESULTS: In untreated AP, the edema, inflammatory infiltration, necrosis and vacuolization increased as compared to control healthy rats (P<0.01). None of the treatment exerted any meaningful effect on the edema and inflammatory infiltration. The selective antagonist increased slightly the necrosis score to 0.82±0.06 at higher dose (P<0.05) vs 0.58±0.06 in untreated AP. The nonselective antagonist increased slightly the vacuolization score to 2.41±0.07 at higher dose (P<0.01) vs 1.88±0.08in untreated AP. The decrease in the number of zymogen granules, disorganization of endoplasmic reticulum,autophagosomes and cytoplasmic vacuoles were more prominent in treated AP than in untreated AP groups.%FAT/TPT in untreated AP increased about four times (18.4±3.8 vs4.8±1.3 in control group without AP, P<0.001).Treatment of AP with both antagonists did not affect significantly augmented trypsinogen activation.CONCLUSION: The treatment with endothelin-1 receptors (non-selective ETA/B and selective ETA) antagonists has essential effect neither on the edema and inflammatory infiltration nor on trypsinogen activation observed in the early course of caerulein-induced AP. Nevertheless a slight increase of the necrosis and vacuolization score and some of the ultrastructural data could suggest the possibility of their undesired effects in caerulein-induced AP at investigated doses. 展开更多
关键词 组织学 胰蛋白酶原 酶活性 急性胰腺炎 小鼠 医学实验
下载PDF
Design and synthesis of 2-alkylbenzimidazole derivatives as novel non-peptide angiotensin Ⅱ AT1 receptor antagonists 被引量:1
9
作者 Jin Yi Xu Qian Ran +3 位作者 Wei Yi Hua Xiao Ming Wu Qiu Juan Wang Jing Zhang 《Chinese Chemical Letters》 SCIE CAS CSCD 2007年第3期251-254,共4页
A series of 2-alkylbenzimidazole derivatives 9a-n have been designed and synthesized as a novel class of non-peptide angiotensin H AT1 receptor antagonists. The synthesized compounds were evaluated for their antagonis... A series of 2-alkylbenzimidazole derivatives 9a-n have been designed and synthesized as a novel class of non-peptide angiotensin H AT1 receptor antagonists. The synthesized compounds were evaluated for their antagonism of angiotensin H, induced contraction in the rabbit thoracic aortic ring and the results showed that compounds 9a, 9g and 9j exhibited potent antagonistic activity of AT1 receptor. 展开更多
关键词 2-Alkylbenzimidazole AT1 receptor antagonists SYNTHESIS HYPERTENSION
下载PDF
血清iNOS、TREM-1、IL-1Ra表达与细菌感染性肠炎患者病情严重程度的关系及其临床意义研究
10
作者 梁丹红 梁民联 +2 位作者 黄换桂 王家华 郑一沣 《中国现代医学杂志》 CAS 2024年第11期72-77,共6页
目的探究细菌感染性肠炎患者血清诱导型一氧化氮合酶(iNOS)、髓样细胞触发受体-1(TREM-1)和白细胞介素-1受体拮抗剂(IL-1Ra)表达的临床意义。方法前瞻性选取2021年2月—2023年2月广州中医药大学东莞医院收治的120例细菌感染性肠炎患者... 目的探究细菌感染性肠炎患者血清诱导型一氧化氮合酶(iNOS)、髓样细胞触发受体-1(TREM-1)和白细胞介素-1受体拮抗剂(IL-1Ra)表达的临床意义。方法前瞻性选取2021年2月—2023年2月广州中医药大学东莞医院收治的120例细菌感染性肠炎患者为研究对象。采集患者粪便标本,分析感染病原菌的病原学特点;根据病情严重程度将患者分为轻度组28例、中度组79例和重度组13例。另选取同期本院体检的健康体检者60例为对照组。比较各组炎症因子[血清降钙素原(PCT)、C反应蛋白(CRP)]、iNOS、TREM-1、IL-1Ra水平;采用Pearson相关分析iNOS、TREM-1、IL-1Ra与炎症因子水平的相关性;采用受试者工作特征(ROC)曲线分析血清iNOS、TREM-1、IL-1Ra对重度细菌感染性肠炎的诊断价值。结果120例细菌感染性肠炎患者共检出176株病原菌,其中氏阳性菌38株(21.59%),革兰阴性菌138株(78.41%)。4组血清PCT、CRP、iNOS、TREM-1、IL-1Ra水平比较,差异均有统计学意义(P<0.05);重度组、中度组、轻度组和对照组依次降低(P<0.05)。Pearson相关性分析结果显示,iNOS、TREM-1、IL-1Ra水平与PCT、CRP水平均呈正相关(P<0.05)。ROC曲线分析结果显示,iNOS最佳截断值为50.07 ng/L,诊断重度细菌感染性肠炎的敏感性和特异性分别为76.92%(95%CI:0.462,0.950)、81.31%(95%CI:0.726,0.882);TREM-1最佳截断值为70.11 pg/mL,诊断的敏感性和特异性分别为84.62%(95%CI:0.546,0.981)、85.05%(95%CI:0.769,0.912);IL-1Ra最佳截断值为271.75 ng/L,诊断的敏感性和特异性分别为92.31%(95%CI:0.640,0.998)、66.36%(95%CI:0.566,0.752)。结论细菌感染性肠炎患者血清iNOS、TREM-1、IL-1Ra表达升高,与患者病情严重程度存在相关性;三者在诊断重度细菌感染性肠炎方面具有良好的诊断价值,或可作为临床评估细菌感染性肠炎病情的潜在指标。 展开更多
关键词 细菌感染性肠炎 诱导型一氧化氮合酶 髓样细胞触发受体-1 IL-1受体拮抗剂 预测价值
下载PDF
神经激肽1受体拮抗剂替代地塞米松二联方案预防中度致吐风险化疗所致恶心呕吐的随机对照试验
11
作者 聂吴仪 周娟 +2 位作者 程东海 王浩强 谢波 《海军军医大学学报》 CAS CSCD 北大核心 2024年第4期462-469,共8页
目的比较神经激肽1(NK-1)受体拮抗剂(RA)联合托烷司琼与地塞米松联合托烷司琼预防中度致吐风险化疗所致恶心呕吐(MEC-CINV)的效果。方法采用非劣效性试验设计,将中国人民解放军南部战区总医院肿瘤科2021年4月至2022年1月满足条件的拟接... 目的比较神经激肽1(NK-1)受体拮抗剂(RA)联合托烷司琼与地塞米松联合托烷司琼预防中度致吐风险化疗所致恶心呕吐(MEC-CINV)的效果。方法采用非劣效性试验设计,将中国人民解放军南部战区总医院肿瘤科2021年4月至2022年1月满足条件的拟接受中度致吐风险化疗的肿瘤患者按照随机数字表法分为NK-1 RA组和地塞米松组。NK-1 RA组患者采用NK-1 RA(阿瑞匹坦或福沙匹坦)+托烷司琼二联止吐方案,地塞米松组采用托烷司琼+地塞米松标准二联止吐方案。主要评价指标为总观察期(0~120 h)、延迟期(24~120 h)、急性期(24 h内)的呕吐完全缓解(CR)率,次要评价指标为各期恶心完全控制(CC)率及恶心呕吐总缓解(TR)率,安全性指标为止吐药物的不良反应(包括乏力、便秘、呃逆、失眠等症状指标,以及白细胞计数减少、中性粒细胞计数减少、血红蛋白下降、血小板计数减少、丙氨酸转氨酶和/或天冬氨酸转氨酶升高、血肌酐升高等实验室指标异常)。采用差异性检验(检验水准为0.05)和非劣效性检验(非劣效性界值为15%,检验水准为0.025)比较两组的干预效果。结果最终共有101例患者全程参与本研究,其中NK-1 RA组51例,地塞米松组50例。NK-1 RA组和地塞米松组总观察期呕吐CR率分别为58.8%(30/51)和56.0%(28/50),非劣效性检验无统计学意义[P_(非劣效)=0.035,率差(RD)=2.80%,95%CI-16.5%~22.1%];急性期呕吐CR率分别为80.4%(41/51)和78.0%(39/50),非劣效性检验有统计学意义(P_(非劣效)=0.016,RD=2.40%,95%CI-13.4%~18.2%);延迟期呕吐CR率分别为62.7%(32/51)和58.0%(29/50),非劣效性检验有统计学意义(P_(非劣效)=0.021,RD=4.70%,95%CI-14.4%~23.8%)。NK-1 RA组各期恶心CC率略高于地塞米松组,非劣效性检验有统计学意义(均P_(非劣效)<0.025)。两组间各安全性指标差异无统计学意义(均P>0.05)。结论在MEC-CINV患者中,NK-1 RA联合托烷司琼的二联止吐方案对恶心呕吐的控制效果非劣效于地塞米松联合托烷司琼标准二联止吐方案,且安全性良好。 展开更多
关键词 中度致吐风险化疗 恶心 呕吐 5-羟色胺3受体拮抗剂 神经激肽1受体拮抗剂 地塞米松
下载PDF
白细胞介素-1受体拮抗剂与骨关节炎及亚型的孟德尔随机化研究
12
作者 陈继鑫 周沁心 +3 位作者 郭天赐 余伟杰 叶云天 刘爱峰 《医学研究杂志》 2024年第4期46-51,共6页
目的 采用双样本孟德尔随机化(Mendelian randomization, MR)的研究方法,评估白细胞介素-1受体拮抗剂(interleukin-1 receptor antagonist, IL-1RA)与骨关节炎及亚型骨关节炎的因果关系。方法 IL-1RA与骨关节炎、膝骨关节炎、髋骨关节... 目的 采用双样本孟德尔随机化(Mendelian randomization, MR)的研究方法,评估白细胞介素-1受体拮抗剂(interleukin-1 receptor antagonist, IL-1RA)与骨关节炎及亚型骨关节炎的因果关系。方法 IL-1RA与骨关节炎、膝骨关节炎、髋骨关节炎的单核苷酸多态性位点(single nucleotide polymorphism, SNP)来自公开的全基因组关联研究汇总数据集,选取密切相关的SNP作为工具变量(instrumental variable, IV)。筛选敏感度试验,MR多效性残差和采用离群值检验来验证所识别的IV的异质性和多效性。采用5种不同的模型,包括逆方差加权模型(inverse-variance weighted, IVW)、加权中值估计模型、基于加权模型的方法、MR-Egger回归和简单众数法进行MR分析。结果 研究不存在异质性。固定效应模型的IVW显示,IL-1RA与骨关节炎(OR=1.06,95%CI:1.01~1.11)、膝骨关节炎(OR=1.07,95%CI:1.01~1.13)之间有显著的因果关系,与髋骨关节炎之间具有相关性,因果关系不显著。敏感度分析显示,研究结果具有稳健性。结论 MR研究支持IL-1RA水平与骨关节炎、膝骨关节炎的发病风险具有因果关系。 展开更多
关键词 白细胞介素-1受体拮抗剂 骨关节炎 孟德尔随机化研究
下载PDF
ANALYSIS OF INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM IN CHINESE PATIENTS WITH ALZHEIMER'S DISEASE 被引量:1
13
作者 ShengBi De-shengWang +1 位作者 Guo-linLi Shang-haPan 《Chinese Medical Sciences Journal》 CAS CSCD 2004年第2期93-96,共4页
Objective To identify an interaction between the interleukin-1 receptor antagonist gene polymorphism and risk of Al-zheimer’s disease. Methods The study included 117 healthy controls, 85 patients with Alzheimer’s di... Objective To identify an interaction between the interleukin-1 receptor antagonist gene polymorphism and risk of Al-zheimer’s disease. Methods The study included 117 healthy controls, 85 patients with Alzheimer’s disease in a Northeastern Chinese popu-lation of Han nationality. Genotypes were determined by a polymerase chain reaction amplification of the intron 2 fragment, harbouring a variable number of short tandem nucleotide sequences. Amplification products were separated on a 2% agarose gel. Results The allele 2 frequency was 27% in healthy controls, and 21% in patients with Alzheimer’s disease. Thus for all-ele 2 as well as for all other alleles, genotypes, or carriage rates, no significant differences compared with controls. Conclusions No association of interleukin-1 receptor antagonist gene polymorphism with Alzheimer’s disease was iden-tified in this population. It is also possible that the increased risk and disease modifying effects are caused by linkage disequ-ilibrium with other genomic variants in other nearby genes. 展开更多
关键词 白细胞介素-1 受体 基因多肽性 阿尔海默氏病 神经系统
下载PDF
Simulation of the oxidative metabolization pattern of netupitant,an NK1 receptor antagonist,by electrochemistry coupled to mass spectrometry
14
作者 Ruxandra Chira Jens Fangmeyer +4 位作者 Ioan O.Neaga Valentin Zaharia Uwe Karst Ede Bodoki Radu Oprean 《Journal of Pharmaceutical Analysis》 SCIE CAS CSCD 2021年第5期661-666,共6页
Considering the frequent use of netupitant in polytherapy,the elucidation of its oxidative metabolization pattern is of major importance.However,there is a lack of published research on the redox behavior of this nove... Considering the frequent use of netupitant in polytherapy,the elucidation of its oxidative metabolization pattern is of major importance.However,there is a lack of published research on the redox behavior of this novel neurokinin-1 receptor antagonist.Therefore,this study was performed to simulate the intensive hepatic biotransformation of netupitant using an electrochemically driven method.Most of the known enzyme-mediated reactions occurring in the liver(i.e.,N-dealkylation,hydroxylation,and Noxidation)were successfully mimicked by the electrolytic cell using a boron-doped diamond working electrode.The products were separated by reversed-phase high-performance liquid chromatography and identified by high-resolution mass spectrometry.Aside from its ability to pinpoint formerly unknown metabolites that could be responsible for the known side effects of netupitant or connected with any new perspective concerning future therapeutic indications,this electrochemical process also represents a facile alternative for the synthesis of oxidation products for further in vitro and in vivo studies. 展开更多
关键词 Netupitant Oxidative metabolism neurokinin-1 antagonist EC/LC/MS
下载PDF
Evaluation of a novel angiotensin II receptor 1 antagonist intesartan as anti-hypertension drug
15
《中国药理学通报》 CAS CSCD 北大核心 2015年第B11期148-148,共1页
Aim The preclinical studies of a novel angiotensin II receptor 1 antagonist 2-(4-( (1,7'-dimethyl-2'- propyl-1H ,3 'H-2,5'-bibenzo [ d ] imidazol-3'-yl ) methyl) -1H-indol-l-yl ) benzoic acid ( intesartan ... Aim The preclinical studies of a novel angiotensin II receptor 1 antagonist 2-(4-( (1,7'-dimethyl-2'- propyl-1H ,3 'H-2,5'-bibenzo [ d ] imidazol-3'-yl ) methyl) -1H-indol-l-yl ) benzoic acid ( intesartan ). Methods The affinity to AT1 receptor of intesartan was tested through radioactive receptor binding assay by -y-counter. The anti-hypertensive activity in spontaneously hypertensive rats (SHRs) at different doses in vivo was tested by tail noninvasive arterial blood pressure measurement system. Pharmacokinetic parameters were analyzed by high per- formance liquid chromatography (HPLC) method. Besides, acute toxicity tests in ICR and Ames reverse mutation assay in tester strain (TA97, TA98, TA100 and TA102) was also detected. Results The binding assays sugges- ted that intesartan displayed high affinity to angiotensin II AT1 receptor with an ICs0 value of (0.36 ± 0. 18) nmol · L^-1. In vivo anti-hypertensive experiments showed that intesartan had an efficient and long-acting effect in reduc- ing blood pressure which could last more than 24 h at the doses of 2 mg· kg^-1, 5 mg · kg^-1 , and 10 mg · kg^-1 in spontaneously hypertensive rats. The minimum effective dose of it was 2 mg · kg^-1 and the T/P value was 54. 18%. Acute toxicity tests suggested that intesartan was safe with the LDs0 value of 526.20 mg · kg^-1. Ames assay proved that it would not cause the mutations of salmonella typhimurium. And the pharmacokinetic experiments showed that it could be absorbed efficiently and metabolized smoothly both in blood and in tissues in wistar rats. Conclusions Intesartan could be considered as a novel anti-hypertension candidate with efficient, long-acting and low toxicity chracteristics. 展开更多
关键词 ANGIOTENSIN II ANGIOTENSIN II receptor 1 antagonist ANTI-HYPERTENSIVE acute toxicity AMES assay metabolism
下载PDF
The interleukin-1 receptor antagonist (IL-1-Ra) and soluble tumor necrosis factor receptor I (sTNF RI) in periodontal disease
16
作者 Sylwia M. Slotwinska 《Open Journal of Immunology》 2013年第1期10-16,共7页
The course and severity of periodontitis can be significantly affected by bacterial virulence as well as host immunity dysfunction. Periodontal tissue destruction has been proved to result from cascade of cytokines sy... The course and severity of periodontitis can be significantly affected by bacterial virulence as well as host immunity dysfunction. Periodontal tissue destruction has been proved to result from cascade of cytokines synthesized by reactive cells upon stimulation by pathogenic bacteria and lipopolysaccharides within their cell membranes. The clinical use of genetically programmed cells, producing substances blocking IL-1, based on recombinant IL-1 antagonist, as well as cytokines activating fibroblasts and osteoblasts to regenerate the destroyed periodontal tissue could prove alternative to the conventional treatment. Another cytokine of interest in respect to periodontitis ethiopathogenesis is soluble tumor necrosis factor receptor I (sTNF RI). Observation of soluble TNF receptors as physiologic inhibitors of TNF led to its administration in therapeutic process as well as in therapy selected cases of aggressive periodontitis. 展开更多
关键词 Periodontitis INTERLEUKIN-1 receptor antagonist (IL-1 Ra) Soluble Tumor Necrosis Factor receptor I (sTNF RI)
下载PDF
Hypoxia inducible factor 1α promotes interleukin-1 receptor antagonist expression during hepatic ischemia-reperfusion injury
17
作者 Zhao-Yang Wang Yu Liu +7 位作者 Shi-Peng Li Jian-Jun Li Zhen Zhang Xue-Chun Xiao Yang Ou Hang Wang Jin-Zhen Cai Shuang Yang 《World Journal of Gastroenterology》 SCIE CAS 2022年第38期5573-5588,共16页
BACKGROUND Ischemia-reperfusion injury(IRI) is a major risk associated with liver surgery and transplantation,and its pathological mechanism is complex.Interleukin-1 receptor antagonist(IL-1ra) can protect the liver f... BACKGROUND Ischemia-reperfusion injury(IRI) is a major risk associated with liver surgery and transplantation,and its pathological mechanism is complex.Interleukin-1 receptor antagonist(IL-1ra) can protect the liver from IRI.However,the regulatory mechanism of IL-1ra expression is still unclear.AIM To identify the mechanism that could protect the liver in the early stage of IRI.METHODS To screen the key genes in hepatic IRI,we performed RNA sequencing and gene enrichment analysis on liver tissue from mice with hepatic IRI.Subsequently,we verified the expression and effect of IL-1ra in hepatic IRI.We also used promoter mutagenesis and chromatin immunoprecipitation assay to search for the transcriptional regulatory sites of hypoxia-inducible factor(HIF)-1α.Finally,to explore the protective mechanism of ischemic preconditioning(IP),we examined the expression of HIF-1α and IL-1ra after IP.RESULTS We identified IL-1ra as a key regulator in hepatic IRI.The expression of IL-1ra was significantly upregulated after hepatic IRI both in vivo and in vitro.Furthermore,we found that HIF-1αregulated Il-1ra transcription in response to hypoxia.Increased HIF-1α accumulation promoted IL-1ra expression,whereas inhibition of HIF-1α exhibited the opposite effect.We also confirmed a predominant role for hypoxia response element in the regulation of Il1ra transcription by HIF-1αactivation.Of note,we demonstrated that IP protects against hepatic IRI by inducing IL-1ra expression,which is mediated through HIF-1α.CONCLUSION We demonstrated that ischemia or hypoxia leads to increased expression of IL-1ra through HIF-1α.Importantly,IP protects the liver from IRI via the HIF-1α–IL-1ra pathway. 展开更多
关键词 Hepatic ischemia-reperfusion injury Interleukin-1 receptor antagonist Hypoxia inducible factor 1α Ischemic preconditioning
下载PDF
Novel Method for Synthesis of Diarylpyrazole Derivatives as Cannabinoid CB_1 Receptor Antagonists
18
作者 WU Ying-qiu ZHENG Guo-jun +2 位作者 WANG Ya-ping WANG Xiang-jing XIANG Wen-sheng 《Chemical Research in Chinese Universities》 SCIE CAS CSCD 2011年第1期66-69,共4页
A novel and efficient method was developed for the synthesis of diarylpyrazole derivatives as cannabinoid CB1 receptor antagonist via four step reactions. The key step was the synthesis of a diarylpyrazole skeleton, w... A novel and efficient method was developed for the synthesis of diarylpyrazole derivatives as cannabinoid CB1 receptor antagonist via four step reactions. The key step was the synthesis of a diarylpyrazole skeleton, which involved initial condensation of the sodium salt of compound 12 with diazonium compounds, and further cyclization by heating at reflux in acetic acid. Eight diarylpyrazole derivatives and nine new synthesized compounds were characterized by 1H NMR, IR, MS, and elemental analysis. The reaction conditions were mild and the overall yields of the target compounds ranged from 26% to 44%. 展开更多
关键词 Cannabinoid CB1 receptor antagonist Diarylpyrazole derivative SR141716
下载PDF
Inhibition of Osteoarthritis in Rats by Electroporation with Interleukin-1 Receptor Antagonist
19
作者 Zhen Sun Heyong Yin +11 位作者 Xiaoming Yu Xun Sun Bo Xiao Yichi Xu Zhiguo Yuan Haoye Meng Jiang Peng Changlong Yu Yu Wang Quanyi Guo Aiyuan Wang Shibi Lu 《Journal of Biomedical Science and Engineering》 2016年第7期323-336,共14页
Gene therapy constitutes a promising strategy for the treatment of osteoarthritis (OA). We assessed the use of electroporation (EP) of non-viral gene vectors, and compared its efficacy with that of adeno-associated vi... Gene therapy constitutes a promising strategy for the treatment of osteoarthritis (OA). We assessed the use of electroporation (EP) of non-viral gene vectors, and compared its efficacy with that of adeno-associated virus (AAV) vectors. EP- and AAV-mediated delivery of human interleukin-1 receptor antagonist (hIL-1Ra) was localized performed in the joints of rats following induction of OA. mRNA levels for hIL-1Ra, IL-1β, TNF-α, MMP-13 and ADAMTS-4 in the cartilage and synovial tissues were analyzed. Structural analyses of the subchondral bone at the medial femoral condyle were performed by Micro-CT after treatment. Knee joint specimens were staining with hematoxylin and eosin and Saffron O. Induction of hIL-1Ra by both EP and AAV inhibited inflammatory-induced sub-chondral bone reconstruction, and effectively suppressed IL-1β activity, as evidenced by decreased expression of MMP-13 and ADAMTS-4. Histological analyses revealed significant protection of cartilage, proteoglycan by EP and AAV. hIL-1Ra expression was similar in both the EP and AAV groups. Notably, this gene is not easier degraded transduced by EP compared with AAV. Taken together, these results show that EP offers transfection efficiency comparable to that of AAV, with the potential for longer gene expression, making EP a promising candidate for efficient non-viral delivery of OA gene therapy. 展开更多
关键词 ELECTROPORATION Interleukin-1 receptor antagonist Adeno-Associated Virus Gene Therapy OSTEOARTHRITIS CARTILAGE SYNOVIUM
下载PDF
非酒精性脂肪性肝病患者血清IL-1RA、CTRP13和CK-18水平变化及其临床意义探讨
20
作者 高洋 张静 卢宣霖 《实用肝脏病杂志》 CAS 2024年第2期185-188,共4页
目的探讨非酒精性脂肪性肝病(NAFLD)患者血清白细胞介素-1受体拮抗剂(IL-1RA)、补体C1q肿瘤坏死因子相关蛋白13(CTRP13)和细胞角蛋白18(CK-18)水平变化及其临床意义。方法2021年1月~2023年1月我院收治的67例NAFLD患者和55例健康体检者,... 目的探讨非酒精性脂肪性肝病(NAFLD)患者血清白细胞介素-1受体拮抗剂(IL-1RA)、补体C1q肿瘤坏死因子相关蛋白13(CTRP13)和细胞角蛋白18(CK-18)水平变化及其临床意义。方法2021年1月~2023年1月我院收治的67例NAFLD患者和55例健康体检者,经肝活检诊断肝脏脂肪变性分级,采用ELISA法检测血清IL-1RA、CTRP13和CK-18水平。应用多元Logistic回归分析危险因素。结果NAFLD组血清IL-1RA和CTRP13水平分别为(328.6±54.3)pg/ml和(2634.2±397.5)pg/ml,显著低于健康人组【分别为(673.1±125.4)pg/ml和(3425.7±423.8)pg/ml,P<0.05】,而血清CK-18水平为(15.2±3.1)ng/ml,显著高于健康人组【(3.9±0.7)ng/ml,P<0.05】;17例F3级肝脂肪变性患者血清IL-1RA和CTRP13水平分别为(256.3±47.6)pg/ml和(2056.3±308.4)pg/ml,显著低于29例F1级患者【分别为(388.3±59.4)pg/ml和(3071.5±409.3)pg/ml,P<0.05】或21例F2级患者【分别为(304.7±50.1)pg/ml和(2498.1±374.2)pg/ml,P<0.05】,而血清CK-18水平为(23.4±4.7)ng/ml,显著高于F1级患者【(8.1±1.3)ng/ml,P<0.05】或F2级患者【(18.5±2.9)ng/ml,P<0.05】;F3级肝脂肪变性患者肥胖、合并糖尿病、合并高脂血症、有代谢综合征家族史、血清IL-1RA≥256.5pg/ml、CTRP13≥2056.5pg/ml和CK-18≥21.6 ng/ml占比分别为70.6%、76.5%、88.2%、70.6%、35.3%、35.3%和70.6%,与50例F1/F2级的38.0%、42.0%、40.0%、30.0%、92.0%、80.0%和10.0%比,差异显著(P<0.05);多因素Logistic回归分析表明,肥胖【OR(95%)为2.0(1.1~3.6)】、合并糖尿病【OR(95%)为2.1(1.1~4.1)】、合并高脂血症【OR(95%)为1.6(1.0~2.6)】、IL-1RA【OR(95%)为0.5(0.3~0.9)】、CTRP13【OR(95%)为0.5(0.3~0.9)】和CK-18【OR(95%)为1.7(1.2~2.5)】为影响NAFLD患者肝脏脂肪变性程度的危险因素(P<0.05)。结论NAFLD患者血清IL-1RA、CTRP13和CK-18水平异常变化可能为评估肝脏脂肪变性程度提供一定的依据。 展开更多
关键词 非酒精性脂肪性肝病 白细胞介素-1受体拮抗剂 补体C1q肿瘤坏死因子相关蛋白13 细胞角蛋白18 临床意义
下载PDF
上一页 1 2 26 下一页 到第
使用帮助 返回顶部